FDA seeks public input on ibogaine trial safety

FDA Seeks Public Input on Ibogaine Trial Safety

The U.S. Food and Drug Administration (FDA) is calling for public feedback on safety protocols and clinical trial designs for ibogaine, a psychedelic compound under investigation for treating opioid use disorder and post-traumatic stress disorder (PTSD). This initiative is part of a broader federal effort to explore psychedelic medicines for serious mental health conditions, according to MyChesCo.

What the FDA is Considering

The FDA is examining protocols for early-stage ibogaine studies, focusing on dosing, patient eligibility, and monitoring for cardiac and neurological issues. The agency's request for information follows an April 2026 executive order aimed at accelerating research into psychedelic treatments for mental illnesses. Michael Davis, director of the FDA’s Center for Drug Evaluation and Research, emphasized the need for high-quality data to guide clinical research while prioritizing patient safety.

Safety Concerns and Trial Design

The FDA is evaluating whether initial trials should involve small participant groups receiving incrementally increased doses, with a maximum dose of 10 milligrams per kilogram of body weight. Other considerations include the selection of participants, conditions that may warrant halting a trial, and measures to prevent adverse cardiac and neurological events. Recommendations on informed consent and independent monitoring are also being sought to protect trial participants.

Federal Support and Research Priorities

Federal health officials have identified adults with opioid use disorder and PTSD as priority groups for ibogaine research. The Department of Health and Human Services, through the Advanced Research Projects Agency for Health, is funding early-phase trials to gather safety and efficacy data. Additionally, the National Institute on Drug Abuse is financing research into ibogaine for opioid use disorder. The FDA has also approved an early-stage study of noribogaine hydrochloride, an ibogaine derivative, for alcohol use disorder under an Investigational New Drug application.

Why It Matters

The FDA's consultation underscores the importance of balancing potential therapeutic benefits of ibogaine against its known safety risks. The agency's efforts to gather public input aim to ensure that early-phase research is conducted with robust safety measures, which could pave the way for broader clinical development. This initiative reflects growing interest in psychedelic compounds as potential treatments for complex mental health conditions.

Interested parties have until November 20, 2026, to submit comments electronically at regulations.gov under Docket No. FDA-2026-N-10429 or via mail to the FDA's Dockets Management Staff in Rockville, MD. The feedback will inform the FDA's approach to ibogaine research moving forward.

Reporting based on MyChesCo. Read the original: [link].